Dr. Ludford is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Boston, MA 02115Phone+1 617-732-5500
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Brigham and Women's HospitalResidency, Internal Medicine, 2014 - 2017
Yale School of MedicineClass of 2014
Certifications & Licensure
FL State Medical License 2021 - Present
GA State Medical License 2022 - 2026
AL State Medical License 2022 - 2025
AZ State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
OK State Medical License 2022 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsSustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination.Kristen Simmons, Jane V Thomas, Kaysia Ludford, Jason A Willis, Victoria S Higbie
Cancer Research Communications. 2023-12-11 - 4 citationsEndoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer.Daniel A Fox, Deepak Bhamidipati, Tsuyoshi Konishi, Harmeet Kaur, Nancy You
European Journal of Cancer. 2023-11-01 - 30 citationsSelective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.Faisal Fa'ak, Maryam Buni, Adewunmi Falohun, Huifang Lu, Juhee Song
Journal for Immunotherapy of Cancer. 2023-06-01
Lectures
- Evaluation of complete pathological remission rates in surgically resected MSI-high metastatic colorectal cancers (mCRC).2019 ASCO Annual Meeting - 6/1/2019
- Phase II trial of nab-paclitaxel (ABI) and ipilimumab (ipi) in patients with treatment naïve metastatic melanoma.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
MD Anderson Research Highlights Special Edition: ESMO 2024September 10th, 2024- Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer TreatmentFebruary 23rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
